XFOR Historical Income Statement
| XFOR Stock | USD 0.59 0.07 10.61% |
Historical analysis of X4 Pharmaceuticals income statement accounts such as Interest Income of 3.5 M, Depreciation And Amortization of 398.1 K, Interest Expense of 3 M or Selling General Administrative of 19.2 M can show how well X4 Pharmaceuticals performed in making a profits. Evaluating X4 Pharmaceuticals income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of X4 Pharmaceuticals's future profits or losses.
Financial Statement Analysis is much more than just reviewing and examining X4 Pharmaceuticals latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether X4 Pharmaceuticals is a good buy for the upcoming year.
XFOR |
About XFOR Income Statement Analysis
X4 Pharmaceuticals Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to X4 Pharmaceuticals shareholders. The income statement also shows XFOR investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).
X4 Pharmaceuticals Income Statement Chart
Add Fundamental
Other Operating Expenses
Other Operating Expenses is the expense which generally does not depend on sales or production quantities of X4 Pharmaceuticals. It is also known as X4 Pharmaceuticals overhead expenses. Typically these expenses include marketing, rent and utilities, office, leases, and other overhead cost. Expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production.Total Operating Expenses
The total costs associated with the day-to-day operations of a business, excluding the cost of goods sold but including selling, general, and administrative expenses.Most accounts from X4 Pharmaceuticals' income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into X4 Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Current Watchlist to better understand how to build diversified portfolios, which includes a position in X4 Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in persons. To learn how to invest in XFOR Stock, please use our How to Invest in X4 Pharmaceuticals guide.At this time, X4 Pharmaceuticals' Interest Income is relatively stable compared to the past year. As of 11/13/2024, Total Other Income Expense Net is likely to grow to about 6.8 M, while Depreciation And Amortization is likely to drop slightly above 398.1 K.
| 2021 | 2022 | 2023 | 2024 (projected) | Depreciation And Amortization | 1.9M | 2.0M | 419K | 398.1K | Interest Income | 10K | 219K | 3.3M | 3.5M |
X4 Pharmaceuticals income statement Correlations
Click cells to compare fundamentals
X4 Pharmaceuticals Account Relationship Matchups
High Positive Relationship
High Negative Relationship
X4 Pharmaceuticals income statement Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Interest Income | 1.2M | 273K | 10K | 219K | 3.3M | 3.5M | |
| Depreciation And Amortization | 7.8M | 351K | 1.9M | 2.0M | 419K | 398.1K | |
| Interest Expense | 2.1M | 2.7M | 3.6M | 4.0M | 5.8M | 3.0M | |
| Selling General Administrative | 17.6M | 20.9M | 24.7M | 27.0M | 32.1M | 19.2M | |
| Other Operating Expenses | 47.8M | 62.9M | 75.3M | 88.1M | 107.5M | 60.5M | |
| Operating Income | (51.7M) | (59.9M) | (85.1M) | (87.6M) | (107.5M) | (102.1M) | |
| Ebit | (51.7M) | (59.9M) | (67.5M) | (90.6M) | (107.5M) | (102.1M) | |
| Research Development | 30.2M | 41.9M | 50.6M | 61.1M | 72.0M | 42.2M | |
| Ebitda | (43.9M) | (59.5M) | (65.6M) | (88.6M) | (107.1M) | (101.7M) | |
| Total Operating Expenses | 47.8M | 62.9M | 75.3M | 88.1M | 107.5M | 60.5M | |
| Income Before Tax | (52.8M) | (62.0M) | (88.7M) | (93.8M) | (101.1M) | (96.0M) | |
| Total Other Income Expense Net | (1.1M) | (2.1M) | (3.6M) | (6.3M) | 6.4M | 6.8M | |
| Net Income Applicable To Common Shares | (53.4M) | (62.1M) | (102.6M) | (96.4M) | (86.8M) | (82.4M) | |
| Net Income | (56.6M) | (62.1M) | (88.7M) | (93.9M) | (101.2M) | (96.1M) | |
| Income Tax Expense | 3.8M | 148K | 17K | 28K | 78K | 74.1K | |
| Net Interest Income | (950K) | (2.4M) | (3.6M) | (3.8M) | (1.7M) | (1.8M) | |
| Gross Profit | (672K) | 3M | (1.9M) | (2.0M) | (2.0M) | (1.9M) | |
| Net Income From Continuing Ops | (52.8M) | (62.1M) | (88.7M) | (93.9M) | (111.1M) | (105.6M) | |
| Reconciled Depreciation | 103K | 351K | 499K | 513K | 481K | 361.0K |
Pair Trading with X4 Pharmaceuticals
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if X4 Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in X4 Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.Moving together with XFOR Stock
Moving against XFOR Stock
| 0.68 | DRUG | Bright Minds Biosciences | PairCorr |
| 0.54 | DMAC | DiaMedica Therapeutics | PairCorr |
| 0.53 | SABSW | SAB Biotherapeutics | PairCorr |
| 0.42 | VIGL | Vigil Neuroscience | PairCorr |
| 0.38 | EQ | Equillium | PairCorr |
The ability to find closely correlated positions to X4 Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace X4 Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back X4 Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling X4 Pharmaceuticals to buy it.
The correlation of X4 Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as X4 Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if X4 Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for X4 Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Additional Tools for XFOR Stock Analysis
When running X4 Pharmaceuticals' price analysis, check to measure X4 Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy X4 Pharmaceuticals is operating at the current time. Most of X4 Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of X4 Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move X4 Pharmaceuticals' price. Additionally, you may evaluate how the addition of X4 Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.